Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Entrada Therapeutics, Inc.TRDA · Entity 2163 | Chief Medical Officer | September 01, 2023 | September 06, 2023 |
| Rezolute, Inc.RZLT · Entity 1990 | Director | November 19, 2025 | November 21, 2025 |
| Tectonic Therapeutic, Inc.AVRO · Entity 5328 | Chief Medical Officer | October 08, 2018 | October 10, 2018 |
| Xeris Biopharma Holdings, Inc.XERS · Entity 4670 | Director | July 01, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Entrada Therapeutics, Inc.
Report date September 01, 2023 · Filed September 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,037 |
Ending reported balance
After 2023-09-06 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2023-09-01 · Grant · Acquired 14,200 · Balance 41,330 F1: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2024; (ii) 25% on September 1, 2025; (iii) 25% on September 1, 2026 and (iv) the remaining 25% on September 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. Row 2 · 2023-09-05 · Tax withholding · Disposed 401 · Balance 40,929 F2: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs. Row 3 · 2023-09-06 · Sale · Disposed 871 · Balance 40,058 F3: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2023-09-06 · Sale · Disposed 21 · Balance 40,037 F3: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.41 · Expires 2033-09-01 | Direct | 21,500 |
Reported balance
After 2023-09-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-09-01 · Grant · Acquired 21,500 · Balance 21,500 F5: 25% of the option shares shall vest and become exercisable on September 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on September 1, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2024; (ii) 25% on September 1, 2025; (iii) 25% on September 1, 2026 and (iv) the remaining 25% on September 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.
F2: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs.
F3: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: 25% of the option shares shall vest and become exercisable on September 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on September 1, 2027.
Rezolute, Inc.
Report date November 19, 2025 · Filed November 21, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 58,576 |
Reported balance
After 2025-11-19 transaction · row 1
1 source rowRow 1 · 2025-11-19 · Grant · Acquired 21,000 · Balance 58,576 F1: Represents grant of restricted stock units which fully vest on December 1, 2026. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.16 · Expires 2035-11-19 | Direct | 12,000 |
Reported balance
After 2025-11-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-11-19 · Grant · Acquired 12,000 · Balance 12,000 F2: The options fully vest on December 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents grant of restricted stock units which fully vest on December 1, 2026.
F2: The options fully vest on December 1, 2026.
Tectonic Therapeutic, Inc.
Report date October 08, 2018 · Filed October 10, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,942 |
Reported balance
After 2018-10-08 transaction · row 1
1 source rowRow 1 · 2018-10-08 · Exercise / conversion · Acquired 2,942 · Balance 2,942 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.91 · Expires 2027-06-12 | Direct | 24,629 |
Reported balance
After 2018-10-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-10-08 · Exercise / conversion · Disposed 2,942 · Balance 24,629 F1: 25% of the shares vested on June 13, 2018 and the remaining 75% vest in equal monthly installments thereafter over a three-year period. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares vested on June 13, 2018 and the remaining 75% vest in equal monthly installments thereafter over a three-year period.
Xeris Biopharma Holdings, Inc.
Report date July 01, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,582 |
Reported balance
After 2026-07-01 transaction · row 1
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 33,582 · Balance 33,582 F1: These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued service on the Company's Board of Directors through such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2036-07-01 | Direct | 37,910 |
Reported balance
After 2026-07-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-01 · Grant · Acquired 37,910 · Balance 37,910 F2: These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in equal annual installments over three years, subject to continued service on the Company's Board of Directors through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued service on the Company's Board of Directors through such vesting date.
F2: These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in equal annual installments over three years, subject to continued service on the Company's Board of Directors through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2026 Filed Jul 2, 2026 22:01 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantStock Option (Right to Buy) · Derivative | 37,910 | $8.00 Strike: $8.00 | $303,280.00 |
DisclosureSEC source: 0001741850-26-000002 · wk-form4_1783029712.xml · derivative · entry 2 KREHER NERISSA · CIK 0001741850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,910 Underlying: Common Stock · 37,910 shares Expires 2036-07-01 F2 · derivative.exercise_date: These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in equal annual installments over three years, subject to continued service on the Company's Board of Directors through such vesting date. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 22:01 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantCommon Stock | 33,582 | $0.00 | $0.00 |
DisclosureSEC source: 0001741850-26-000002 · wk-form4_1783029712.xml · nonDerivative · entry 1 KREHER NERISSA · CIK 0001741850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,582 F1 · shares: These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued service on the Company's Board of Directors through such vesting date. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 22:21 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantDirector Stock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $10.16 | $0.00 |
DisclosureSEC source: 0000912282-25-001290 · form4.xml · derivative · entry 2 KREHER NERISSA · CIK 0001741850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Shares · 12,000 shares Expires 2035-11-19 F2 · derivative.exercise_date: The options fully vest on December 1, 2026. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 22:21 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantCommon Shares | 21,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-001290 · form4.xml · nonDerivative · entry 1 KREHER NERISSA · CIK 0001741850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,576 F1 · shares: Represents grant of restricted stock units which fully vest on December 1, 2026. Read SEC document |
| June 13, 2025 Filed Jun 23, 2025 13:12 UTC | Rezolute, Inc. RZLT · Entity 1990 | PurchaseCommon Shares | 3,076 | $3.25 | $9,997.00 |
DisclosureSEC source: 0000912282-25-000699 · form4.xml · nonDerivative · entry 1 KREHER NERISSA · CIK 0001741850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,576 Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 22:52 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantDirector Stock Options (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.39 | $0.00 |
DisclosureSEC source: 0000912282-25-000668 · form4.xml · derivative · entry 2 KREHER NERISSA · CIK 0001741850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Shares · 5,000 shares Expires 2035-06-10 F2 · derivative.exercise_date: The options vest 100% on July 1, 2026. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 22:52 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantCommon Shares | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000668 · form4.xml · nonDerivative · entry 1 KREHER NERISSA · CIK 0001741850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,500 F1 · shares: Represents grant of restricted stock units which vest 100% on July 1, 2026. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 02:18 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantDirector Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.61 | $0.00 |
DisclosureSEC source: 0000912282-25-000178 · form4.xml · derivative · entry 2 KREHER NERISSA · CIK 0001741850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2035-02-16 F2 · derivative.exercise_date: The options vest 100% on March 1, 2026. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 02:18 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantCommon Shares | 25,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000178 · form4.xml · nonDerivative · entry 1 KREHER NERISSA · CIK 0001741850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,500 F1 · shares: Represents grant of restricted stock units which vest 100% on March 1, 2026. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 17:04 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantDirector Stock Options (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0000912282-24-000075 · form4.xml · derivative · entry 1 KREHER NERISSA · CIK 0001741850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2034-01-23 F1 · derivative.exercise_date: The options vest in 36 equal monthly installments, beginning February 23, 2024. Read SEC document |
| September 06, 2023 Filed Sep 6, 2023 21:08 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 21 | $14.00 | $294.00 |
DisclosureSEC source: 0001689375-23-000062 · wf-form4_169403451511634.xml · nonDerivative · entry 4 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,037 F3 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023. Read SEC document |
| September 06, 2023 Filed Sep 6, 2023 21:08 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 871 | $13.46 | $11,727.75 |
DisclosureSEC source: 0001689375-23-000062 · wf-form4_169403451511634.xml · nonDerivative · entry 3 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,058 F3 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 21:08 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 401 | $14.46 | $5,799.46 |
DisclosureSEC source: 0001689375-23-000062 · wf-form4_169403451511634.xml · nonDerivative · entry 2 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,929 F2 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 21:08 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 21,500 | $0.00 Strike: $15.41 | $0.00 |
DisclosureSEC source: 0001689375-23-000062 · wf-form4_169403451511634.xml · derivative · entry 5 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,500 Underlying: Common Stock · 21,500 shares Expires 2033-09-01 F5 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on September 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on September 1, 2027. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 21:08 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantCommon Stock | 14,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001689375-23-000062 · wf-form4_169403451511634.xml · nonDerivative · entry 1 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,330 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2024; (ii) 25% on September 1, 2025; (iii) 25% on September 1, 2026 and (iv) the remaining 25% on September 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. Read SEC document |
| August 04, 2023 Filed Aug 4, 2023 20:50 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,898 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001689375-23-000050 · wf-form4_169118219238022.xml · derivative · entry 11 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,012 Underlying: Common Stock · 6,898 shares Expires 2030-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023. F6 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| August 04, 2023 Filed Aug 4, 2023 20:50 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 6,898 | $14.14 | $97,521.16 |
DisclosureSEC source: 0001689375-23-000050 · wf-form4_169118219238022.xml · nonDerivative · entry 8 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,130 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 04, 2023 Filed Aug 4, 2023 20:50 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 6,898 | $2.10 | $14,485.80 |
DisclosureSEC source: 0001689375-23-000050 · wf-form4_169118219238022.xml · nonDerivative · entry 7 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,028 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023. Read SEC document |
| August 03, 2023 Filed Aug 4, 2023 20:50 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,464 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001689375-23-000050 · wf-form4_169118219238022.xml · derivative · entry 10 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 94,910 Underlying: Common Stock · 9,464 shares Expires 2030-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023. F6 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| August 03, 2023 Filed Aug 4, 2023 20:50 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 9,464 | $14.74 | $139,529.64 |
DisclosureSEC source: 0001689375-23-000050 · wf-form4_169118219238022.xml · nonDerivative · entry 6 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,130 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.44 to $15.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 03, 2023 Filed Aug 4, 2023 20:50 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 9,464 | $2.10 | $19,874.40 |
DisclosureSEC source: 0001689375-23-000050 · wf-form4_169118219238022.xml · nonDerivative · entry 5 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023. Read SEC document |
| August 02, 2023 Filed Aug 4, 2023 20:50 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,348 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001689375-23-000050 · wf-form4_169118219238022.xml · derivative · entry 9 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,374 Underlying: Common Stock · 10,348 shares Expires 2030-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023. F6 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| August 02, 2023 Filed Aug 4, 2023 20:50 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 68 | $16.82 | $1,143.76 |
DisclosureSEC source: 0001689375-23-000050 · wf-form4_169118219238022.xml · nonDerivative · entry 4 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,130 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023. Read SEC document |
| August 02, 2023 Filed Aug 4, 2023 20:50 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 1,000 | $16.01 | $16,011.70 |
DisclosureSEC source: 0001689375-23-000050 · wf-form4_169118219238022.xml · nonDerivative · entry 3 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,198 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.75 to $16.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 02, 2023 Filed Aug 4, 2023 20:50 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 9,280 | $15.09 | $140,012.93 |
DisclosureSEC source: 0001689375-23-000050 · wf-form4_169118219238022.xml · nonDerivative · entry 2 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,198 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.74 to $15.71, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 02, 2023 Filed Aug 4, 2023 20:50 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 10,348 | $2.10 | $21,730.80 |
DisclosureSEC source: 0001689375-23-000050 · wf-form4_169118219238022.xml · nonDerivative · entry 1 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 21:32 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 164 | $11.22 | $1,840.52 |
DisclosureSEC source: 0001689375-23-000011 · wf-form4_167787905815593.xml · nonDerivative · entry 4 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,330 F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.04 to $11.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 21:32 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 1,477 | $10.49 | $15,495.50 |
DisclosureSEC source: 0001689375-23-000011 · wf-form4_167787905815593.xml · nonDerivative · entry 3 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,494 F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.04 to $11.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 21:32 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Tax withholdingCommon Stock | 945 | $11.60 | $10,958.41 |
DisclosureSEC source: 0001689375-23-000011 · wf-form4_167787905815593.xml · nonDerivative · entry 2 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,971 F2 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:32 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 43,000 | $0.00 Strike: $12.25 | $0.00 |
DisclosureSEC source: 0001689375-23-000011 · wf-form4_167787905815593.xml · derivative · entry 5 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,000 Underlying: Common Stock · 43,000 shares Expires 2033-03-01 F6 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on March 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2027. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:32 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantCommon Stock | 28,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001689375-23-000011 · wf-form4_167787905815593.xml · nonDerivative · entry 1 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,916 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2024; (ii) 25% on March 1, 2025; (iii) 25% on March 1, 2026 and (iv) the remaining 25% on March 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2024; (ii) 25% on March 1, 2025; (iii) 25% on March 1, 2026 and (iv) the remaining 25% on March 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. Read SEC document |
| March 01, 2023 Filed Apr 19, 2023 21:48 UTC Amendment | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 21,500 | $0.00 Strike: $12.25 | $0.00 |
DisclosureSEC source: 0001689375-23-000027 · wf-form4a_168194087335878.xml · derivative · entry 2 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,500 Underlying: Common Stock · 21,500 shares Expires 2033-03-01 F3 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on March 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2027. F2 · balance_after: The Reporting Person's original Form 4, filed on March 3, 2023, is being amended by this Form 4A solely to correct an administrative error, which misreported a grant that occurred on March 1, 2023 as a total of 43,000 option shares and 28,400 RSUs, when in fact 21,500 option shares and 14,200 RSUs were granted as of that date, accurately reflecting that these grants are semi-annual. As a result of this administrative error, the number of shares beneficially owned by the Reporting Person following the corrected transaction reflects a reduction by 50% in the number of RSUs and option shares, respectively, reported as beneficially owned by the Reporting Person by 21,500 option shares and 14,200 RSUs, respectively. Read SEC document |
| March 01, 2023 Filed Apr 19, 2023 21:48 UTC Amendment | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantCommon Stock | 14,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001689375-23-000027 · wf-form4a_168194087335878.xml · nonDerivative · entry 1 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,130 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2024; (ii) 25% on March 1, 2025; (iii) 25% on March 1, 2026 and (iv) the remaining 25% on March 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. F2 · balance_after: The Reporting Person's original Form 4, filed on March 3, 2023, is being amended by this Form 4A solely to correct an administrative error, which misreported a grant that occurred on March 1, 2023 as a total of 43,000 option shares and 28,400 RSUs, when in fact 21,500 option shares and 14,200 RSUs were granted as of that date, accurately reflecting that these grants are semi-annual. As a result of this administrative error, the number of shares beneficially owned by the Reporting Person following the corrected transaction reflects a reduction by 50% in the number of RSUs and option shares, respectively, reported as beneficially owned by the Reporting Person by 21,500 option shares and 14,200 RSUs, respectively. Read SEC document |
| December 30, 2022 Filed Jan 3, 2023 21:32 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 5,200 | $13.45 | $69,931.68 |
DisclosureSEC source: 0001689375-23-000001 · wf-form4_167278151155209.xml · nonDerivative · entry 1 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,516 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.09 to $14.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 26, 2022 Filed Oct 27, 2022 22:49 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,960 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001689375-22-000039 · wf-form4_166691093179410.xml · derivative · entry 9 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,722 Underlying: Common Stock · 20,716 shares Expires 2030-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. F6 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| October 26, 2022 Filed Oct 27, 2022 22:49 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 4,317 | $22.01 | $95,020.62 |
DisclosureSEC source: 0001689375-22-000039 · wf-form4_166691093179410.xml · nonDerivative · entry 7 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,716 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.79 to $22.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 26, 2022 Filed Oct 27, 2022 22:49 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 643 | $21.21 | $13,638.29 |
DisclosureSEC source: 0001689375-22-000039 · wf-form4_166691093179410.xml · nonDerivative · entry 6 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,033 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.79 to $21.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 26, 2022 Filed Oct 27, 2022 22:49 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 4,960 | $2.10 | $10,416.00 |
DisclosureSEC source: 0001689375-22-000039 · wf-form4_166691093179410.xml · nonDerivative · entry 5 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,676 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. Read SEC document |
| October 25, 2022 Filed Oct 27, 2022 22:49 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,040 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001689375-22-000039 · wf-form4_166691093179410.xml · derivative · entry 8 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,682 Underlying: Common Stock · 25,033 shares Expires 2030-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. F6 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. F7 · balance_after: The Form 4 filed by the reporting person on September 12, 2022 inadvertently understated the number of shares remaining subject to this option following the transactions reported therein by 111,690 shares, an error that was carried forward onto the reporting person's subsequent Form 4 filings. Prior to the transactions reported herein, the correct number of shares remaining subject to this option was 127,722 shares. Read SEC document |
| October 25, 2022 Filed Oct 27, 2022 22:49 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 100 | $22.13 | $2,213.00 |
DisclosureSEC source: 0001689375-22-000039 · wf-form4_166691093179410.xml · nonDerivative · entry 4 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,716 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. Read SEC document |
| October 25, 2022 Filed Oct 27, 2022 22:49 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 2,998 | $21.42 | $64,215.06 |
DisclosureSEC source: 0001689375-22-000039 · wf-form4_166691093179410.xml · nonDerivative · entry 3 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,816 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.01 to $21.895, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 25, 2022 Filed Oct 27, 2022 22:49 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 4,942 | $20.53 | $101,461.73 |
DisclosureSEC source: 0001689375-22-000039 · wf-form4_166691093179410.xml · nonDerivative · entry 2 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,814 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 25, 2022 Filed Oct 27, 2022 22:49 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 8,040 | $2.10 | $16,884.00 |
DisclosureSEC source: 0001689375-22-000039 · wf-form4_166691093179410.xml · nonDerivative · entry 1 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. Read SEC document |
| September 28, 2022 Filed Sep 28, 2022 21:10 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,122 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001689375-22-000033 · wf-form4_166439943270541.xml · derivative · entry 10 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,032 Underlying: Common Stock · 3,122 shares Expires 2030-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. F6 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| September 28, 2022 Filed Sep 28, 2022 21:10 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 3,122 | $15.25 | $47,609.56 |
DisclosureSEC source: 0001689375-22-000033 · wf-form4_166439943270541.xml · nonDerivative · entry 7 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,716 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 28, 2022 Filed Sep 28, 2022 21:10 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 3,122 | $2.10 | $6,556.20 |
DisclosureSEC source: 0001689375-22-000033 · wf-form4_166439943270541.xml · nonDerivative · entry 6 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. Read SEC document |
| September 27, 2022 Filed Sep 28, 2022 21:10 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,403 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001689375-22-000033 · wf-form4_166439943270541.xml · derivative · entry 9 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,154 Underlying: Common Stock · 2,403 shares Expires 2030-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. F6 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| September 27, 2022 Filed Sep 28, 2022 21:10 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 2,403 | $15.31 | $36,788.97 |
DisclosureSEC source: 0001689375-22-000033 · wf-form4_166439943270541.xml · nonDerivative · entry 5 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,716 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 27, 2022 Filed Sep 28, 2022 21:10 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 2,403 | $2.10 | $5,046.30 |
DisclosureSEC source: 0001689375-22-000033 · wf-form4_166439943270541.xml · nonDerivative · entry 4 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,119 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. Read SEC document |
| September 26, 2022 Filed Sep 28, 2022 21:10 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,068 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001689375-22-000033 · wf-form4_166439943270541.xml · derivative · entry 8 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,557 Underlying: Common Stock · 3,068 shares Expires 2030-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. F6 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.